Accelerating Clinical Trials Ltd

A not-for-profit company, any surplus income is reinvested for blood cancer patients’ benefit.

Delivery of both academic investigator initiated and industry sponsored clinical trials in haemato-oncology are accelerated with the resource and expertise of ACT and the networks, TAP and IMPACT.